EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 369 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Expressive Writing, What is It? May 12, 2021 Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... December 11, 2023 A Cancer Revolution comes to Manchester: Patrick’s review November 24, 2021 Discovering the BRCA2 gene – 25 years on January 14, 2021 Load more HOT NEWS Cancer in My Community: Expanding Genetic Testing in Thailand FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in... TRACERx: Using blood tests to track lung cancer
